Skip to main content

NRX Pharmaceuticals, Inc.

NRXP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001719406

No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding NRX Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of NRXP: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders37130−6
Shares3.64M43.5K4.12M+521.9K (+14.5%)
Value$2.18M$24.0K$3.04M+$887.0K (+41.1%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (2)

Institutions that held NRX Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to NRXP in Q3 2022
InstitutionSharesValue% of portfolio
Texas Capital Bank Wealth Management Services Inc63,290$47.0K0.01%
China Universal Asset Management Co., Ltd.633$00.00%

Sold out (8)

Institutions that held NRX Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of NRXP in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Millennium Management LLC296,815$178.0K
Sabby Management, LLC200,000$120.0K
Citadel Advisors LLC91,666$55.0K
Two Sigma Investments, LP41,451$25.0K
UBS Group AG16,798$10.0K
Virtu Financial LLC12,799$8.00K
Wealthcare Advisory Partners LLC13,000$8.00K
Penserra Capital Management LLC10,157$6.00K

Not filed for Q3 2022 yet (1)

Institutions that held NRX Pharmaceuticals, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NRXP in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
HighPoint Advisor Group LLC43,501$24.0K